

Amivantamab Supplementary table

Table 1: Exploratory analysis of ORR by clinical and demographic subgroups

Characteristics	Responders	Response Rate (95% CI)
Age		
≥65 (n=33)	11	33 (18, 52)
<65 (n=48)	21	44 (29, 59)
Sex		
Female (n=48)	17	35 (22, 51)
Male (n=33)	15	45 (28, 64)
Race		
White (n=30)	13	43 (25, 63)
Black or African American (n=2)	1	50 (1, 99)
Asian (n=40)	17	42 (27, 59)
Other (n=9)	1	11 (0, 48)
Prior Systemic Therapy		
Immunotherapy (n=37)	17	46 (29, 63)
No prior immunotherapy (n=44)	15	34 (21, 50)
EGFR TKI (n=18)	9	50 (26, 74)

Source: RYBREVANT approval package (16)